OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - OmniAb, Inc. reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.14, marking an earnings surprise of -14.29% [1] - The company's revenues for the quarter ended September 2024 were $4.17 million, missing the Zacks Consensus Estimate by 52.95$5.48 million a year ago [2] - The stock has underperformed, losing about 25.5% since the beginning of the year, while the S&P 500 gained 25.8% [3] Financial Performance - Over the last four quarters, OmniAb has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of$12.14 million, and for the current fiscal year, it is -$0.58 on revenues of$32.3 million [7] Industry Context - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of OmniAb's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]